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Abstract
Background:  It  has  been  demonstrated  that  there  are  a  lot  of  different  prognostic  factors  which
are worthy  of  consideration  whereas  diabetes  mellitus  (DM)  has  not  been  clearly  or  consis-
tently identiﬁed  as  a  prognostic  value  in  advanced  non-small  cell  lung  cancer  (NSCLC).  The  aim
of this  study  was  to  investigate  the  prognostic  signiﬁcance  of  the  characteristics  of  patients
in advanced  NSCLC.  Speciﬁcally,  we  investigated  the  impact  of  DM  for  progression-free  sur-
vival (PFS)  and  overall  survival  (OS)  in  patients  receiving  ﬁrst-line  platinum-based  doublets
chemotherapy.
Methods: We  retrospectively  reviewed  442  patients  with  advanced  NSCLC.  DM  and  other  poten-
tial prognostic  variables  were  chosen  for  analysis  in  this  study.  Univariate  and  multivariate
analyses were  conducted  to  identify  prognostic  factors  associated  with  survival.
Result: The  results  of  univariate  analysis  for  OS  were  identiﬁed  as  having  prognostic  sig-
niﬁcance: performance  status  (p  <  0.001),  stage  (p  <  0.001),  DM  (p  <  0.001),  liver  metastasis
(p =  0.02)  and  brain  metastasis  (p  <  0.001).  Stage,  diabetes  mellitus,  and  liver  metastasis  were
identiﬁed  as  having  prognostic  signiﬁcance  for  PFS.
Multivariate  analysis  showed  that  poor  performance  status,  presence  of  DM  and  advanced
stage were  considered  independent  negative  prognostic  factors  for  OS  (p  0.001,  p  <  0.001  and
p <  0.001  respectively).  Furthermore,  DM  and  stage  were  considered  independent  negative  pro-
gnostic factors  for  PFS  (p  0.005  and  p  0.001  respectively).
Conclusion:  In  conclusion,  DM  at  the  time  of  diagnosis  was  associated  with  the  negative  pro-
gnostic importance  for  PFS  and  OS  in  the  advanced  stage  patients  who  were  receiving  ﬁrst-linehemotherapy.  In  addition  poor  performance  status  and  advancedplatinum-based  doublets  c
stage were  identiﬁed  as  negative  prognostic  factors.
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reserved.
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Será  a  diabetes  mellitus  um  fator  de  prognóstico  negativo  no  tratamento  do
carcinoma  pulmonar  de  não  pequenas  células  em  estadio  avanc¸ado?
Resumo
Antecedentes:  Existem  vários  factores  de  prognóstico  previamente  estabelecidos  no  carcinoma
pulmonar de  não  pequenas  células  (NSCLC)  avanc¸ado.  Até  à  presente  data,  a  diabetes  mellitus
(DM) não  foi  identiﬁcada  de  forma  consistente  como  potencial  factor  de  prognóstico  neste
contexto.  O  objectivo  do  presentes  estudo  é  investigar  o  signiﬁcado  prognóstico  das  diferentes
características  dos  doentes  com  NSCLC  avanc¸ada.  Especiﬁcamente,  investigámos  o  impacto  da
DM para  a  sobrevivência  livre  de  progressão  (PFS)  e  sobrevivência  global  (OS)  em  doentes  em
regime duplo  de  quimioterapia  de  primeira  linha  à  base  de  platina.
Métodos:  Analisámos  retrospectivamente  442  doentes  com  NSCLC  avanc¸ado.  Foram  escolhidas
a DM  e  outras  potenciais  variáveis  de  prognóstico  para  a  análise  neste  estudo.  Foram  realizadas
análises  univariadas  e  multivariadas  para  identiﬁcar  os  factores  de  prognóstico  associados  à
sobrevivência.
Resultados:  Os  resultados  de  análise  univariada  para  OS  identiﬁcaram  como  tendo  signiﬁcân-
cia para  o  prognóstico:  estado  geral  (p  <0,001),  estádio  (p  <0,001),  DM  (p  <0,001),  metástases
hepáticas  (p  =  0,02)  e  metástases  no  cérebro  (p  <0,001).  O  estádio,  diabetes  mellitus  e  as  metás-
tases hepáticas  foram  identiﬁcadas  como  tendo  signiﬁcância  de  prognóstico  para  a  PFS.A  análise
multivariada  mostrou  que  um  mau  estado  geral,  a  presenc¸a  de  DM  e  um  estádio  avanc¸ado
foram considerados  factores  de  prognóstico  negativo  independentes  para  OS  (p  0,001;  p  <0,001
e p  <0,001;  respectivamente).  Além  disso,  a  DM  e  estádio  foram  considerados  factores  de
prognóstico  negativo  independentes  para  a  PFS  (p  0,005  e  p  0,001;  respectivamente).
Conclusões:  Em  conclusão,  a  DM  na  altura  do  diagnóstico  comportou-se  como  um  fator  de
prognóstico  negativo  para  a  PFS  e  OS  nos  doentes  em  estádio  avanc¸ado  que  estavam  em  regime
duplo de  quimioterapia  de  primeira  linha  à  base  de  platina.  Além  do  mau  estado  geral,  os
estádios avanc¸ados  foram  identiﬁcados  como  factor  de  prognóstico  negativo.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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Lung  cancer  is  the  most  common  of  all  cancer  deaths  in
both  men  and  women  worldwide.  NSCLC  represents  80--85%
of  all  diagnosed  lung  cancers  cases.1 Surgery  is  the  only
curative  treatment  option  for  patients  with  NSCLC.  At  the
time  of  diagnosis,  two-third  of  patients  with  lung  can-
cer  are  diagnosed  with  locally  advanced  or  metastatic
disease.  The  median  survival  time  for  advanced  disease
is  5.8--12.6  months  and  the  overall  5-year  survival  rate
among  this  patient  population  is  still  less  than  10%.2,3
Systemic  chemotherapy  with  the  platinum-based  doublets
are  currently  recommended  as  a  standard  of  ﬁrst-line
chemotherapy  for  treatment  of  NSCLC.4
An  increased  incidence  of  the  NSCLC  is  connected  with
aging,5 which  explains  why  NSCLC  frequently  appears  simul-
taneously  with  other  age-related  diseases  such  as  diabetes
mellitus  (DM).  Various  studies  have  indicated  that  among
patients  with  colorectal,6 pancreatic,7 breast,8 or  liver9
cancer,  existing  DM  was  associated  with  a  lower  long-
term  survival.  The  prognostic  signiﬁcance  of  pre-existing
DM  in  patients  with  lung  cancer  was  evaluated.10--18 Three
studies10--12 reported  a  decrease  in  survival  in  patients  with
DM  compared  to  those  without  DM.  On  the  other  hand,  sev-
eral  studies  have  shown  that  DM  was  associated  with  an
equal13--15 or  an  increased  chance  of  survival.16--18 The  effect
of  DM  on  patients  with  NSCLC  remains  uncertain.  In  addition
to  this,  DM  has  not  been  clearly  or  consistently  identiﬁed
t
v
gs  a  prognostic  value  for  the  recurrence  or  progression  of
dvanced  NSCLC.6,11--14 The  aim  of  this  study  was  to  inves-
igate  the  impact  of  DM  for  PFS  and  OS  on  the  patients
eceiving  ﬁrst-line  platinum-based  doublets  chemotherapy.
ethods
e  retrospectively  reviewed  442  patients  with  histological
r  cytological  proven  NSCLC  who  were  receiving  ﬁrst-line
latinum-based  doublets  chemotherapy  between  August
002  and  February  2012.  They  had  to  meet  the  following
nclusion  criteria;  (1)  they  had  a histological  or  cytological
iagnosis  of  locally  advanced  and/or  metastatic  NSCLC;  (2)
hey  were  18  years  of  age  or  older;  (3)  they  had  had  no  pre-
ious  chemotherapy  or  radiotherapy;  (4)  they  had  to  have
 measurable  disease,  as  deﬁned  by  Response  Evaluation
riteria  in  Solid  Tumors  RECIST.
Patients  were  identiﬁed  as  having  DM  on  the  basis  of  ele-
ated  fasting  glucose  level  (>126  mg/dL),  and  a  history  of
M  or  medication  use,  such  as  insulin  or  oral  hypoglycemic
gents.  Prevalent  hypertension  was  deﬁned  as  systolic  pres-
ure  ≥140  mm  Hg  and/or  diastolic  ≥90  diastolic  and/or
urrently  taking  antihypertensive  medications.Twelve  potential  prognostic  variables  were  chosen  on
he  basis  of  previously  published  clinical  trials.19--24 The
ariables  were  divided  into  categories:  age  (<70  or  ≥70),
ender  (male  or  female),  Eastern  Cooperative  Oncology
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roup  (ECOG)  performance  status  (0--1  or  2--3),  stage  (III
r  IV),  histology  (squamous  cell  carcinoma  or  adenocar-
inoma),  weight  loss  ≥5%  within  the  previous  3  months
present  or  absent),  DM  (present  or  absent),  hypertension
present  or  absent),  smoking  history  (present  or  absent),
econd-line  chemotherapy  (present  or  absent),  liver  metas-
asis  (present  or  absent)  and  brain  metastasis  (present  or
bsent)  at  the  time  of  ﬁrst-line  chemotherapy  administra-
ion.
All  of  the  analyses  were  performed  using  the  SPSS  sta-
istical  software  program  package  (SPSS  version  11.5  for
indows).  The  differences  in  the  clinical  characteristics
etween  the  two  groups  were  analyzed  by  a  chi-square  test
nd  a  student  t  test.  OS  was  calculated  from  the  start  of  the
rst  cycle  of  chemotherapy  to  the  date  of  death  from  any
ause  or  the  date  of  the  last  follow-up.  PFS  was  deﬁned  as
he  time  from  the  ﬁrst  day  of  chemotherapy  till  progression
r  death.  OS  and  PFS  were  estimated  using  the  Kaplan--Meier
n
n
t
t
Table  1  Characteristics  of  diabetic  and  non-diabetic  NSCLC  patie
Characteristic  With  DM  
No  (%)  
Enrolled  patients.  66  14.9  
Sex
Male 56  84.8  
Female 10  15.2  
Age, years
<70  54  81.8  
≥70 12  18.2  
Performance  status  (%)
0--1  30  45.5  
2--3 16  24.2  
Unknown 20  30.3  
Smoking history
Current  or  former  40  60.6  
Never 6  9.1  
Unknown 20  30.3  
Weight loss
Yes  5  7.6  
No 40  60.6  
Unknown 21  31.8  
Metastatic sites  (%)
Liver  10  15.1  
Brain 11  16.7  
Stage (%)
III  28  42.4  
IV 38  57.6  
Hypertension
Yes 15  22.7  
No 51  77.3  
First-line chemotherapy
GemCis  19  28.8  
DocCis 23  34.8  
PacCis 19  28.8  
Other 13  7.6  
Second-line  chemotherapy  19  28.6  A.  Inal  et  al.
ethod.  The  Cox  proportional  hazards  regression  model  was
sed  to  determine  statistical  signiﬁcant  variables  related  to
urvival.  Differences  were  assumed  to  be  signiﬁcant  when  P
alue  was  less  than  0.05.
esults
etween  August  2002  and  February  2012,  442  patients  with
dvanced  NSCLC  were  enrolled  in  this  study.  There  were
6  patients  (M:  56,  F:  10)  on  DM  side  and  376  patients
M:  328,  F:  48)  on  the  non-diabetic  side.  DM  patients  were
lder  than  the  non-diabetic  patients  (median  60  versus  58,
 >  0.05).  HT  was  more  common  on  the  DM  side  than  on  the
on-diabetic  one  (22.7%  versus  8.2%,  p  <  0.0001).  There  was
o  statistical  difference  between  patients  with  the  DM  and
he  non-diabetic  group  in  terms  of  gender,  performance  sta-
us,  stage,  histology,  weight  loss,  smoking  history,  ﬁrst-line
nts.
Without  DM  p
No  (%)
376  85.1
328  87.2  P  >  0.05
48  12.8
327  87.0  P  >  0.05
49  13.0
218  58.0  P  >  0.05
100  26.6
58  15.4
250  66.5
55  14.6  P  >  0.05
71  18.9
77  20.5
238  63.3  P  >  0.05
61  16.2
43  11.4  P  >  0.05
56  14.9
160  42.6
216  57.4  P  >  0.05
31  8.2
345  91.8  P  <  0.001
115  30.5
132  35.0  P  >  0.05
93  24.7
37  9.8
107  28.7  P  >  0.05
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Table  2  Univariate  analysis  of  OS  by  categorical  variable.
Variable  Log-rank  test  value  Degrees  of  freedom  p-Value
Sex  0.87 1  0.35
Age 1.23  1  0.26
Stage 52.5  1  <0.001
Smoking history  2.12  1  0.14
Performance  status  14.8  1  <0.001
Histology 0.18  1  0.66
Weight loss  0.32  1  0.85
DM 15.1  1  <0.001
Hypertension  2.5 1  0.10
Second-line  chemotherapy 3.0 1  0.08
Metastatic sites
Liver  5.3  1  0.02
Brain 29.4  1  <0.001
Table  3  Univariate  analysis  of  PFS  by  categorical  variable.
Variable Log-rank  test  value Degrees  of  freedom p-Value
Sex  1.65  1  0.19
Age 2.47  1  0.11
Stage 19.8  1  <0.001
Smoking history  0.19  1  0.65
Performance  status  0.005  1  0.94
Histology 0.16  1  0.68
Weight loss  0.29  1  0.58
DM 14.5  1  <0.001
Hypertension  1.57  1  0.20
Second-line  chemotherapy 0.62 1  0.43
Metastatic sites
Liver  3.88 0.04
Brain 2.85 1  0.09
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The  prevalence  of  DM  and  cancer  is  increasing  in  cur-
rent  society.  In  our  study,  the  prevalence  of  DM  in  NSCLC
patients  was  14.9%,  about  twice  as  high  as  the  global
Table  4  Multivariate  analysis  of  prognostic  factors.
Factors  OR  %95  CI  p-Value
PFS
DM  1.83  1.20--2.79  0.005
Stage 1.69  1.25--2.30  0.001
OSchemotherapy,  ﬁrst-line  chemotherapy  cycles,  second-
line  chemotherapy  (p  >  0.05).  The  patients’  baseline
characteristics  are  listed  in  Table  1.
The  results  of  univariate  analysis  for  OS  are  summarized
in  Table  2.  Among  the  twelve  variables  of  univariate  analysis,
ﬁve  variables  were  identiﬁed  as  having  prognostic  signif-
icance:  Performance  status  (p  <  0.001),  stage  (p  <  0.001),
diabetes  mellitus  (p  <  0.001),  liver  metastasis  (p  =  0.02)  and
brain  metastasis  (p  <  0.001).
The  results  of  univariate  analysis  for  PFS  are  summa-
rized  in  Table  3.  Three  variables  were  identiﬁed  as  having
prognostic  signiﬁcance:  stage  (p  <  0.001),  diabetes  mellitus
(p  <  0.001),  and  liver  metastasis  (p  =  0.04).
Multivariate  analysis  included  the  prognostic  signiﬁcance
factors  in  univariate  analysis.  The  results  of  multivariate
analysis  are  shown  in  Table  4.  Multivariate  analysis  by  Cox
proportional  hazard  model  showed  that  poor  performance
status,  presence  of  DM  and  advanced  stage  were  consid-
ered  independent  negative  prognostic  factors  for  OS  (p
0.001,  p  <  0.001  and  p  <  0.001  respectively)  (Figs.  1--3).  Fur-
thermore,  DM  and  stage  were  considered  as  independent
negative  prognostic  factors  for  PFS  (p  0.005  and  p  0.001
respectively).iscussion
n  this  retrospective  study,  we  set  out  to  clarify  the  impact
f  DM  on  the  prognosis  of  patients  with  NSCLC.  The  aim  of
his  study  was  to  investigate  the  impact  of  DM  for  PFS  and  OS
n  the  patients  receiving  ﬁrst-line  platinum-based  doublets
hemotherapy.DM 2.38  1.48--3.81  <0.001
Stage 3.76  2.45--5.77  <0.001
Performance  status  1.92  1.32--2.79  0.001
66  A.  Inal  et  al.
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cFigure  1  Survival  of  patients  according  to  DM.
revalence  of  diabetes.19 Epidemiological  evidence  indi-
ates  that  DM  was  found  to  be  common  in  some  cancers  such
s  breast,  colorectum,  liver,  endometrium,  and  pancreas
ancer.24--28 The  prevalence  of  DM  in  newly  diagnosed  can-
er  patients  is  reported  to  be  8--18%  in  the  United  States.29
iabetes  is  generally  characterized  by  insulin  resistance
nd  hyperinsulinemia.30 It  has  been  claimed  that  hyper-
nsulinemia  can  lead  to  increases  in  the  level  of  growth
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us.
ormones  for  malignant  tumors,  which  often  over-express
nsulin  receptors  and  insulin-like  growth  factor.11,31
A  number  of  very  different  trials  have  linked  pre-existing
M  at  the  time  of  diagnosis  with  an  increased  mortality  rate
or  patients  with  pancreatic,8 hepatocellular,9 or  breast10
ancer.  However,  there  are  few  studies  about  the  impact  of
iabetes  mellitus  for  survival  in  lung  cancer.10--18 The  evi-
ence  is  limited  and  conﬂicting,  although  prior  studies16--18
ave  shown  that  pre-existing  DM  at  the  time  of  diagnosis
s  strongly  associated  with  an  increase  in  OS.  On  the  other
and,  other  studies  have  shown  the  association  between  DM
nd  an  equal13--15 or  an  increased  survival  rate.16--18
The  current  study  demonstrated  that  patients  with  DM
n=66)  exhibited  a  signiﬁcant  increase  in  mortality  and
ecurrence  compared  with  those  without  DM  (n  =  376).  Our
etrospective  study  review  suggests  that  DM  is  associated
ith  independent  risk  factors  for  survival.  There  may  be
everal  reasons  for  this.  First,  patients  with  DM  may  present
ith  more  advanced  NSCLC.32 Because  of  concomitant  treat-
ent  of  the  chronic  diseases  associated  with  DM,  patients
ay  not  undergo  routine  screening  for  lung  cancer.33 Sec-
nd,  pre-existing  diabetes  may  have  a  greater  risk  of
hemotherapy-related  toxicity  such  as  febrile  neutrope-
ia,  infection.32 Third,  patients  with  DM  may  receive  less
ggressive  treatment,  (including  chemotherapy,  radiothe-
apy,  and/or  surgery).32
A  poor  PS  is  usually  accepted  as  a  negative  prognostic
actor  for  all  cancer  patients.34,35 The  importance  of  PS  was
lso  conﬁrmed  in  advanced  NSCLC  patients.21,22 Our  results
emonstrated  that  PS  is  associated  with  independent  nega-
ive  risk  factors  for  survival.
22,23Previous  ﬁndings  by  a  number  of  authors have  shown
hat  the  tumor  stage  at  initial  presentation  was  the  most
mportant  prognostic  factor  for  survival  in  patients  with
SCLC.  Similarly,  stage  of  disease  was  found  to  be  an
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independent  negative  prognostic  factor  of  survival  in  the
present  retrospective  study.
The  present  study  has  got  some  limitations.  First  it  is  a
retrospective  study.  Second,  we  did  not  evaluate  the  type  of
DM,  duration  of  diabetes  and  the  types  of  diabetic  therapy
used.  Third,  our  ﬁndings  may  have  a  selection  bias  because
of  the  possibilities  of  undiagnosed  DM  among  patients  clas-
siﬁed  as  not  having  DM.
In  conclusion,  DM  at  the  time  of  diagnosis  was  associated
with  the  negative  prognostic  importance  for  PFS  and  OS  in
advanced  stage  patients  receiving  ﬁrst-line  platinum-based
doublets  chemotherapy.  In  addition,  poor  performance
status  and  advanced  stage  were  identiﬁed  as  negative  pro-
gnostic  factors.  It  may  be  concluded  that  these  ﬁndings  may
also  facilitate  pretreatment  prediction  of  survival  and  can
be  used  for  selecting  patients  for  the  correct  choice  of  treat-
ment.  Therefore,  a  prospective  trial  and  larger  clinical  trials
are  needed.
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